Parkinson's disease Flashcards

1
Q

What is Parkinson’s disease?

A

Parkinson’s disease is a progressive neurodegenerative condition caused by degeneration of dopaminergic neurons in the substantia nigra.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What are the classical features of Parkinson’s disease?

A

The classical triad of features includes bradykinesia, tremor, and rigidity.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

How are the symptoms of Parkinson’s disease characterized?

A

The symptoms are characteristically asymmetrical.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What is the epidemiology of Parkinson’s disease?

A

It is around twice as common in men, with a mean age of diagnosis of 65 years.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What is bradykinesia?

A

Bradykinesia refers to poverty of movement, sometimes called hypokinesia, characterized by short, shuffling steps with reduced arm swinging and difficulty in initiating movement.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What is the nature of tremor in Parkinson’s disease?

A

Tremor is most marked at rest, typically ‘pill-rolling’ in the thumb and index finger, and is worse when stressed or tired but improves with voluntary movement.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What are the types of rigidity associated with Parkinson’s disease?

A

Rigidity can be described as lead pipe or cogwheel, the latter due to superimposed tremor.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What are other characteristic features of Parkinson’s disease?

A

Other features include mask-like facies, flexed posture, micrographia, drooling of saliva, and psychiatric features such as depression.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What psychiatric features are associated with Parkinson’s disease?

A

Depression is the most common feature, affecting about 40%, with possible dementia, psychosis, and sleep disturbances.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What are some additional features of Parkinson’s disease?

A

Impaired olfaction, REM sleep behaviour disorder, fatigue, and autonomic dysfunction such as postural hypotension.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

How does drug-induced parkinsonism differ from Parkinson’s disease?

A

Motor symptoms are generally of rapid onset and bilateral, with rigidity and rest tremor being uncommon.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

How is Parkinson’s disease diagnosed?

A

Diagnosis is usually clinical, but if differentiating between essential tremor and Parkinson’s disease is difficult, NICE recommends considering 123I-FP-CIT single photon emission computed tomography (SPECT).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

A Lewy body (stained brown) in a brain cell of the substantia nigra in Parkinson’s disease. The brown colour is positive immunohistochemistry staining for

A

alpha-synuclein

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Normal substantia nigra vs PD

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

PD drugs MOA

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

PD drugs - effect on motor symptoms, activities of daily living, off time, adverse events, hallucinations

17
Q

PD drugs - effect on motor symptoms, activities of daily living, off time, adverse events, hallucinations

18
Q

Who should diagnose and manage Parkinson’s disease?

A

Parkinson’s disease should only be diagnosed and managed by a specialist with expertise in movement disorders.

19
Q

What are the first-line treatments for Parkinson’s disease based on quality of life?

A

If motor symptoms affect quality of life: levodopa. If not: dopamine agonist (non-ergot derived), levodopa, or MAO-B inhibitor.

20
Q

What are the effects of levodopa compared to dopamine agonists and MAO-B inhibitors?

A

Levodopa provides more improvement in motor symptoms and activities of daily living but has more motor complications. Dopamine agonists and MAO-B inhibitors offer less improvement in these areas.

21
Q

What should be added if a patient continues to have symptoms despite optimal levodopa treatment?

A

NICE recommends adding a dopamine agonist, MAO-B inhibitor, or COMT inhibitor as an adjunct.

22
Q

What are the risks associated with acute akinesia or neuroleptic malignant syndrome?

A

These risks arise if medication is not taken or absorbed, such as during gastroenteritis.

23
Q

What are the common issues with dopaminergic therapy?

A

Impulse control disorders can occur, especially with dopamine agonist therapy, and in patients with a history of impulsive behaviors or alcohol consumption.

24
Q

What should be done if excessive daytime sleepiness develops?

A

Patients should not drive, and medication should be adjusted to control symptoms. Modafinil can be considered if alternative strategies fail.

25
Q

What medication can be considered for orthostatic hypotension?

A

Midodrine can be considered if symptoms persist after a medication review.

26
Q

What is the common combination for levodopa treatment?

A

Levodopa is nearly always combined with a decarboxylase inhibitor (e.g., carbidopa or benserazide) to prevent peripheral metabolism.

27
Q

What are the common adverse effects of levodopa?

A

Common adverse effects include dry mouth, anorexia, palpitations, postural hypotension, and psychosis.

28
Q

What is the ‘on-off’ phenomenon in levodopa treatment?

A

It refers to large variations in motor performance, with normal function during the ‘on’ period and weakness during the ‘off’ period.

29
Q

What are dopamine receptor agonists and their risks?

A

Examples include bromocriptine, ropinirole, and cabergoline. They can cause impulse control disorders and are more likely to cause hallucinations in older patients.

30
Q

What do MAO-B inhibitors do?

A

They inhibit the breakdown of dopamine secreted by dopaminergic neurons.

31
Q

What is the mechanism of action for Amantadine?

A

Its mechanism is not fully understood but likely increases dopamine release and inhibits its uptake at dopaminergic synapses.

32
Q

What are COMT inhibitors used for?

A

They are used as an adjunct to levodopa therapy in patients with established Parkinson’s disease.

33
Q

What are antimuscarinics used for?

A

They block cholinergic receptors and are now used more for drug-induced parkinsonism rather than idiopathic Parkinson’s disease.